Email This Article
Headlines & Perspectives
Vytorin Risks Debated in Medical Journal
By
Elizabeth Trotta
09/02/08 - 02:29 PM EDT
The cholesterol drug, produced by Schering-Plough and Merck, produced a higher rate of cancer vs. a control group in a recent study, but a larger analysis said the results are statistically insignificant.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.12 |
Oil *
77.09
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.67
|
10 Yr
3.21%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-2.04%
|
Data delayed 20 minutes |


Connect with TheStreet